Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury

NCT00310739 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2006-11-07

No results posted yet for this study

Summary

We previously reported early measurement of urinary MDA might be a useful marker for the prediction of CDDP-induced renal damage in rat. The purpose of this clinical study is to test whether the changes of human urinary excretion of MDA, and can be used as early biomarker for the prediction of development of CDDP-induced ARF.

Conditions

Sponsors & Collaborators

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Takayuki Tsuji, MD · Hamamatsu University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310739 on ClinicalTrials.gov